Pfizer (PFE) : The value of composite uptick trades was $71.96 million, whereas, the value of composite downtick trades was $96.84 million. The uptick to downtick ratio stood at 0.74 with a negative money flow of ($24.88) Million during Wednesdays trading session. The block trades money flow was negative ($22.18 million).The uptick to the downtick ratio of 0.42 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $15.82 million. The transaction of the trades on downticks amounted to $38 million, which confirms investors selling on the strength of price. Pfizer (PFE) gained 4 cents at $36.68, an increase of 0.11% over the previous days close.
Also, Jefferies maintains its view on Pfizer (NYSE:PFE) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Jefferies raises the price target from $40 per share to $41.5 per share on Pfizer . The rating by the firm was issued on July 14, 2016.
Pfizer (NYSE:PFE): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $36.90 and $36.68 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $36.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $36.68, notching a gain of 0.11% for the day. The total traded volume was 12,274,287 . The stock had closed at $36.64 on the previous day.
The stock has recorded a 20-day Moving Average of 3.17% and the 50-Day Moving Average is 5.52%. In a related news, Damelio Frank A, officer (Executive Vice President) of Pfizer Inc, unloaded 100,000 shares at an average price of $34.49 on May 26, 2016. The total amount of the transaction was worth $3,449,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.